Finally, the cardiotoxicity associated with cancer therapeutics and Y-PK inhibitor drugs does not appear to be a primary concern for PLK4 targeting with mixed kinase inhibitors as represented by CFI-400945, nor is there an obvious high pharmacogenonomic risk for individual variability in response or toxicity based on CYP2D6 activity. The gene discussed is CYP2D6; the disease is cancer.